Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataXRT for Radiation Dermatitis in Pediatric CNS Tumors
NCT03990597Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 6 weeks and StrataXRT as a preventative agent for radiation-associated dermatitis up to 6 weeks. Planned start Aug 2019; status: withdrawn.
Beyond the preview
Go deeper on NCT03990597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990597.